22 Jan StemSight
Laura Koivusalo, Ph.D., CEO and Founder
April 10 | 4:45pm | Salone dei Cavalieri, Section 2
Tampere, Finland
(Private)
StemSight is developing a unique cell-based approach to treat corneal blindness using allogeneic human induced pluripotent stem cells (iPSCs). Our first product STE-001 is targeting the rare disease limbal stem cell deficiency (LSCD), for which iPSC-derived therapeutic limbal stem cells (LSCs) will be transplanted to restore the natural renewal capacity of the corneal epithelium. We further aim to develop additional products for the treatment of different forms of corneal blindness by further cell therapy products, such as iPSC-derived corneal endothelial cells (CEnC) (STE-002). The company was established around IP developed in Tampere University (Finland) by Professor Heli Skottman and her team. Â Professor Skottman is one of the world’s leading experts in ocular stem cell biology.
